Alkermes
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
POSTED
06-29-20
Alkermes Announces 3rd Annual ALKERMES PATHWAYS RESEARCH AWARDS℠ Program and 2019 Recipients
POSTED
06-24-20
Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities
POSTED
05-07-20
Collaborative and Risk-focused Engagement (CaRE™) at Alkermes
POSTED
05-04-20
Statement from Alkermes on Response to COVID-19
At Alkermes, we are closely monitoring and rapidly responding to the impact of COVID-19 on our employees...
POSTED
05-04-20
Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities
Alkermes plc (Nasdaq: ALKS) today announced that the company is now accepting applications for its newly-established COVID-19 Relief Fund, a special edition of the company's signature Alkermes Inspiration Grants® program. The...
